Children's Hospital New Orleans

Summary

Children's Hospital New Orleans is a medical facility located in New Orleans, Louisiana. This center is recognized for care of Cancer, Acute Lymphoblastic Leukemia, Neuroblastoma, Brain Tumor, Leukemia and other specialties. Children's Hospital New Orleans is involved with conducting 211 clinical trials across 395 conditions. There are 4 research doctors associated with this hospital, such as Lolie C. Yu, Augusto C. Ochoa, Jessica Gautreaux, and Christopher Roth.

Top PIs

Clinical Trials running at Children's Hospital New Orleans

Cancer

Wilms Tumor

Testicular cancer

Acute Lymphoblastic Leukemia

Neuroblastoma

Ovarian Cancer

Lung Cancer

Burkitt Lymphoma

Leukemia

Ovarian Carcinoma

Letermovir

for Preventing Infection After Stem Cell Transplant in Blood Cancer

This phase III single arm trial determines whether taking prophylactic letermovir will reduce the likelihood of infection with cytomegalovirus (CMV) in children and adolescents after stem cell transplant compared to estimated rate of infection without prophylaxis. The treatments used to prepare for HCT reduce the body's natural infection-fighting ability and increase the likelihood of an infection with a virus called cytomegalovirus. "Prophylaxis" means to take a drug to prevent a disease or side effect. Letermovir is an antiviral drug that stops cytomegalovirus from multiplying and may prevent cytomegalovirus infection and make the disease less severe.

Recruiting

2 awards

Phase 3

5 criteria

Chemotherapy

for Cancer

This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumor has spread outside of the organ in which it developed, it is considered metastatic. Chemotherapy drugs, such as bleomycin, carboplatin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The trial studies whether carboplatin or cisplatin is the preferred chemotherapy to use in treating metastatic standard risk germ cell tumors.

Recruiting

2 awards

Phase 3

26 criteria

Triptorelin

for Cancer

This phase III trial compares the effect of giving triptorelin vs no triptorelin in preventing ovarian damage in adolescents and young adults (AYAs) with cancer receiving chemotherapy with an alkylating agents. Alkylating agents are part of standard chemotherapy, but may cause damage to the ovaries. If the ovaries are not working well or completely shut down, then it will be difficult or impossible to get pregnant in the future. Triptorelin works by blocking certain hormones and causing the ovaries to slow down or pause normal activity. The triptorelin used in this study stays active in the body for 24 weeks or about 6 months after a dose is given. After triptorelin is cleared from the body, the ovaries resume normal activities. Adding triptorelin before the start of chemotherapy treatment may reduce the chances of damage to the ovaries.

Recruiting

2 awards

Phase 3

4 criteria